Physiomics Secures Major Contract Extension with Pharma Client

Physiomics ( (GB:PYC) ) has shared an announcement.

Physiomics plc has secured a significant contract extension with a large pharmaceutical client, valued at £143,780, to continue utilizing its Virtual Tumour platform for modeling oncology agents. This extension underscores the company’s strong relationship with the client and highlights the effectiveness of its technology in supporting novel oncology therapies, particularly in combination with other treatment modalities.

Spark’s Take on GB:PYC Stock

According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.

Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.

To see Spark’s full report on GB:PYC stock, click here.

More about Physiomics

Physiomics plc is a company specializing in mathematical modelling, data science, and biostatistics to support the development of new therapeutics and personalized medicine solutions. They focus on streamlining drug development for biotech and pharma companies by deriving insights from diverse data sources to optimize research design across various stages of drug development. Their proprietary Virtual Tumour technology has been instrumental in over 100 commercial projects.

Average Trading Volume: 6,838,733

Technical Sentiment Signal: Sell

Current Market Cap: £1.23M

See more data about PYC stock on TipRanks’ Stock Analysis page.